

MT
PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/00, 38/04, 38/08, 38/10		A3	(11) International Publication Number: WO 99/63945
			(43) International Publication Date: 16 December 1999 (16.12.99)
(21) International Application Number: PCT/US99/13146 (22) International Filing Date: 11 June 1999 (11.06.99)		(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 60/089,055 12 June 1998 (12.06.98) US 60/106,339 30 October 1998 (30.10.98) US		Published <i>With international search report.</i>	
(71) Applicant (for all designated States except US): SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH [US/US]; 1275 York Avenue, New York, NY 10021 (US).		(88) Date of publication of the international search report: 2 March 2000 (02.03.00)	
(72) Inventors; and (75) Inventors/Applicants (for US only): NIKOLIC-ZUGIC, Janko [YU/US]; Sloan-Kettering Institute for Cancer Research, 1275 York Avenue, New York, NY 10021 (US). DYALL, Ruben [MU/US]; Sloan-Kettering Institute for Cancer Research, 1275 York Avenue, New York, NY 10021 (US). HOUGHTON, Alan, N. [US/US]; Sloan-Kettering Institute for Cancer Research, 1275 York Avenue, New York, NY 10021 (US).			
(74) Agents: LARSON, Marina, T. et al.; Oppedahl & Larson LLP, 611 Main Street, P.O. Box 5540, Frisco, CO 80443-5540 (US).			
(54) Title: VACCINATION STRATEGY TO PREVENT AND TREAT CANCERS			
(57) Abstract <p>A cellular immune response is induced to a non-immunogenic or weakly immunogenic target protein expressed by tumor cells, by administering to a mammalian subject an amount of a therapeutic antigen effective to induce a cellular immune response to the target protein. The therapeutic antigen is an immunogenic peptide having an MHC-binding portion which binds to the major histocompatibility complex (MHC) and an immune-recognition portion which is recognized by T-cells. The therapeutic antigen is derived from the non-immunogenic or weakly immunogenic target protein such that the MHC-binding portion binds to MHC with a greater affinity than the target protein without material alteration of the immune-recognition portion. The therapeutic antigen may include a sorting signal which directs the transport of the therapeutic antigen into the endoplasmic reticulum and into the endosome/lysosome to facilitate loading of the peptide onto MHC class I and class II molecules, respectively, to facilitate loading of the protein onto MHC molecules for presentation to the immune system.</p>			